Abstract

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a global population of more than 35 million people living with HIV, there is intense interest in developing a cure for HIV infection. The International AIDS Society convened a group of international experts to develop a scientific strategy for research towards an HIV cure. This Perspective summarizes the group's strategy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    UN Joint Programme on HIV/AIDS (UNAIDS). The Gap Report, 2014; available at: (accessed 23 April 2015).

  2. 2.

    , & Past, present and future: 30 years of HIV research. Nat. Rev. Microbiol. 11, 877–883 (2013).

  3. 3.

    et al. International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607–614 (2012).

  4. 4.

    , , & Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112–1120 (1996).

  5. 5.

    et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74, 6790–6799 (2000).

  6. 6.

    , & Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84, 6425–6437 (2010).

  7. 7.

    et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4, 134–146 (2008).

  8. 8.

    et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013).

  9. 9.

    et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16, 460–465 (2010).

  10. 10.

    et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J. Infect. Dis. 208, 1436–1442 (2013).

  11. 11.

    et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. USA 111, 2307–2312 (2014).

  12. 12.

    et al. Persistent HIV-1 replication maintains the HIV-1 reservoir during therapy. Nature (in the press).

  13. 13.

    et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).

  14. 14.

    et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl. Acad. Sci. USA 110, E4987–E4996 (2013).

  15. 15.

    et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).

  16. 16.

    et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).

  17. 17.

    et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2, e520–e529 (2015).

  18. 18.

    et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21 (2014).

  19. 19.

    et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501 (2012).

  20. 20.

    et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834 (2013).

  21. 21.

    et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J. Clin. Invest. 125, 1901–1912 (2015).

  22. 22.

    et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).

  23. 23.

    et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin. Immunol. 21, 218–226 (2001).

  24. 24.

    , & HIV-1 virion production from single inducible proviruses following T-cell activation ex vivo. J. Virol. 90, 1673–1676 (2015).

  25. 25.

    et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121, 4321–4329 (2013).

  26. 26.

    et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog. 10, e1004287 (2014).

  27. 27.

    , & Targeting HIV transcription: the quest for a functional cure. Curr. Top. Microbiol. Immunol. 389, 121–145 (2015).

  28. 28.

    et al. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. MBio 6, e00465 (2015).

  29. 29.

    & Immunologic strategies for HIV-1 remission and eradication. Science 345, 169–174 (2014).

  30. 30.

    et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893–900 (2009).

  31. 31.

    et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J. Infect. Dis. 208, 1212–1220 (2013).

  32. 32.

    et al. OPTIPRIM ANRS-147 Study Group. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. J. Antimicrob. Chemother. 70, 2108–2120 (2015).

  33. 33.

    et al. HIV-1 persistence in CD4+ T cells with stem cell–like properties. Nat. Med. 20, 139–142 (2014).

  34. 34.

    et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J. Immunol. 178, 6975–6983 (2007).

  35. 35.

    et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132–139 (2015).

  36. 36.

    et al. PD-1 and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. (2016).

  37. 37.

    et al. Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity 41, 493–502 (2014).

  38. 38.

    , , , & HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research. J. Neurovirol. 21, 290–300 (2015).

  39. 39.

    et al. Macrophages sustain HIV replication in vivo independently of T cells. J. Clin. Invest. 126, 1353–1366 (2016).

  40. 40.

    et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570–573 (2014).

  41. 41.

    et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).

  42. 42.

    et al. Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. AIDS 28, 1091–1099 (2014).

  43. 43.

    et al. Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc. Natl. Acad. Sci. USA 113, 1883–1888 (2016).

  44. 44.

    et al. Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog. 9, e1003799 (2013).

  45. 45.

    et al. VRC 101 Study Team. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 207, 1829–1840 (2013).

  46. 46.

    et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013).

  47. 47.

    et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).

  48. 48.

    et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. Science 351, 714–720 (2016).

  49. 49.

    et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989–999 (2014).

  50. 50.

    et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224–228 (2013).

  51. 51.

    et al. VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).

  52. 52.

    et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487–491 (2015).

  53. 53.

    et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc. Natl. Acad. Sci. USA 111, 13151–13156 (2014).

  54. 54.

    & Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res. Hum. Retroviruses 31, 13–24 (2015).

  55. 55.

    et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat. Commun. 6, 8447 (2015).

  56. 56.

    et al. Dual-affinity re-targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125, 4077–4090 (2015).

  57. 57.

    et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J. Clin. Invest. 125, 4497–4513 (2015).

  58. 58.

    et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319–327 (2014).

  59. 59.

    et al. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am. J. Transplant. 14, 1136–1141 (2014).

  60. 60.

    et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS 29, 504–506 (2015).

  61. 61.

    International HIV Controllers Study. et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551–1557 (2010).

  62. 62.

    et al. ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).

  63. 63.

    et al. ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3, e49–e54 (2016).

  64. 64.

    et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74–77 (2014).

  65. 65.

    et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 10, e1003872 (2014).

  66. 66.

    et al. Elevated plasma viral loads in romidepsin-treated simian immunodeficiency virus–infected rhesus macaques on suppressive combination antiretroviral therapy. Antimicrob. Agents Chemother. 60, 1560–1572 (2015).

  67. 67.

    et al. HIV latency in the humanized BLT mouse. J. Virol. 86, 339–347 (2012).

  68. 68.

    et al. Pediatric HIV/AIDS Cohort Study. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr. 168, 1138–1146 (2014).

  69. 69.

    et al. HIV-NAT 194 Study Group. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 28, 1015–1020 (2014).

  70. 70.

    et al. Cell-associated HIV-1 DNA and RNA decay dynamics during early combination antiretroviral therapy in HIV-1-infected infants. Clin. Infect. Dis. 61, 1862–1870 (2015).

  71. 71.

    , & Immunity to HIV in early life. Front. Immunol. 5, 391 (2014).

  72. 72.

    et al. Long-term control of HIV by CCR5 Δ32/Δ32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009).

  73. 73.

    & Chemokine receptor 5 knockout strategies. Curr. Opin. HIV AIDS 6, 74–79 (2011).

  74. 74.

    et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2, 36ra43 (2010).

  75. 75.

    et al. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 122, 179–187 (2013).

  76. 76.

    et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 111, 11461–11466 (2014).

  77. 77.

    et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog. 8, e1002649 (2012).

  78. 78.

    et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).

  79. 79.

    et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

  80. 80.

    et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20, 296–300 (2014).

  81. 81.

    et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87–91 (2015).

  82. 82.

    et al. Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells. Proc. Natl. Acad. Sci. USA 112, 1523–1528 (2015).

  83. 83.

    et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014).

  84. 84.

    et al. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J. Clin. Invest. 120, 2345–2354 (2010).

  85. 85.

    et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).

  86. 86.

    et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549–555 (2005).

  87. 87.

    et al. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J. Infect. Dis. 212, 1361–1365 (2015).

  88. 88.

    et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 111, 7078–7083 (2014).

  89. 89.

    et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine 2, 872–881 (2015).

  90. 90.

    et al. A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loads. J. Infect. Dis. 212, 1387–1396 (2015).

  91. 91.

    et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9, e1003174 (2013).

  92. 92.

    et al. HIV antibody characterization as a method to quantify reservoir size during curative interventions. J. Infect. Dis. 209, 1613–1617 (2014).

  93. 93.

    et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 3, e03821 (2014).

  94. 94.

    et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343–353 (2016).

  95. 95.

    & Absence of HIV-1 after treatment cessation in an infant. N. Engl. J. Med. 370, 678 (2014).

  96. 96.

    et al. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat. Methods 12, 427–432 (2015).

  97. 97.

    et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J. Infect. Dis. 208, 50–56 (2013).

  98. 98.

    et al. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J. Virol. 88, 3516–3526 (2014).

  99. 99.

    et al. Persistence of integrated HIV DNA in CXCR3+CCR6+memory CD4+ T-cells in HIV-infected individuals on antiretroviral therapy. AIDS (in the press).

  100. 100.

    et al. Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment. AIDS 29, 1003–1014 (2015).

  101. 101.

    , & Social and Ethical Working Group on HIV Cure. Social and ethical implications of HIV cure research. AIDS 28, 1247–1250 (2014).

  102. 102.

    The ethics of HIV “cure” research: what can we learn from consent forms? AIDS Res. Hum. Retroviruses 31, 56–63 (2015).

  103. 103.

    & What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. J. Virus Erad. 1, 51–53 (2015).

  104. 104.

    , , & HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives. AIDS Care 28, 524–527 (2016).

  105. 105.

    et al. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS Res. Hum. Retroviruses 31, 78–84 (2015).

  106. 106.

    , , , & Stakeholder engagement in HIV cure research: Lessons learned from other HIV interventions and the way forward. AIDS Patient Care STDS 29, 389–399 (2015).

  107. 107.

    & Advancing community stakeholder engagement in biomedical HIV prevention trials: principles, practices and evidence. Expert Rev. Vaccines 13, 1553–1562 (2014).

  108. 108.

    et al. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One 9, e113031 (2014).

  109. 109.

    et al. The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. J. Virus Erad. 1, 245–249 (2015).

  110. 110.

    Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Global. Health 4, 5 (2008).

  111. 111.

    et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).

  112. 112.

    , & An HIV cure: feasibility, discovery, and implementation. J. Am. Med. Assoc. 312, 335–336 (2014).

  113. 113.

    , , , & Words matter: Discussing research towards an HIV cure in research and clinical contexts. J. Acquir. Immune Defic. Syndr. 67, e110–e111 (2014).

  114. 114.

    et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828–1835 (2013).

  115. 115.

    et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630–634 (2012).

  116. 116.

    et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381–385 (2015).

  117. 117.

    et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl. Acad. Sci. USA 109, 9523–9528 (2012).

  118. 118.

    et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat. Commun. 6, 8495 (2015).

  119. 119.

    et al. ANRS 116 SALTO study group. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS 29, 2003–2007 (2015).

  120. 120.

    et al. EraMune-01 study team. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS 30, 221–230 (2016).

  121. 121.

    et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530, 51–56 (2016).

  122. 122.

    et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 27, 2853–2862 (2013).

  123. 123.

    et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS 28, 1555–1566 (2014).

  124. 124.

    et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12, 452–462 (2013).

  125. 125.

    et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21 (2014).

  126. 126.

    et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527 (2011).

Download references

Acknowledgements

J.L. is supported in part by federal funds from the NCI/NIH under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the DHHS, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. government. The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, the Department of Defense or the US National Institutes of Health. Y.-R.L. is a World Health Organization (WHO) staff member. The opinions herein are those of the authors and should not be construed as official or representing the views of the WHO. The authors acknowledge T. Rasmussen, T. Mota and M. Crane for assistance with preparation of figures.

Author information

Author notes

    • Steven G Deeks
    •  & Sharon R Lewin

    These authors contributed equally to this work.

Affiliations

  1. Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

    • Steven G Deeks
    • , Judith Auerbach
    • , Timothy J Henrich
    •  & Joseph McCune
  2. The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.

    • Sharon R Lewin
  3. Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.

    • Sharon R Lewin
  4. International and Scientific Relations Office, ANRS, Paris, France.

    • Anna Laura Ross
  5. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.

    • Jintanat Ananworanich
  6. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.

    • Jintanat Ananworanich
  7. Molecular Virology Lab, Institute of Human Genetics, CNRS UPR 1142, Université de Montpellier, Montpellier, France.

    • Monsef Benkirane
  8. Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

    • Paula Cannon
  9. CRCHUM and Department of Microbiology, Infectiology, and Immunology, Université de Montréal, Faculty of Medicine, Montréal, Quebec, Canada.

    • Nicolas Chomont
  10. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

    • Daniel Douek
  11. AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA.

    • Jeffrey D Lifson
  12. World Health Organization Regional Office for the Western Pacific, Manila, Philippines.

    • Ying-Ru Lo
  13. Brigham & Women's Hospital, Boston, Massachusetts, USA.

    • Daniel Kuritzkes
    •  & Timothy J Henrich
  14. University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

    • David Margolis
    •  & Gail Henderson
  15. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

    • John Mellors
  16. Johns Hopkins University School of Medicine & Bloomberg School of Public Health, Baltimore, Maryland, USA.

    • Deborah Persaud
  17. University of North Carolina–Project China, Guangzhou, China.

    • Joseph D Tucker
  18. Institut Pasteur, Paris, France.

    • Françoise Barre-Sinoussi
  19. Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.

    • Galit Alter
    •  & Dan H Barouch
  20. Sorbonne Universités, UPMC Univ Paris 06, CIMI–Paris, France.

    • Brigitte Autran
  21. Inserm U1135, CIMI–Paris, Paris, France.

    • Brigitte Autran
  22. AP-HP, Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France.

    • Brigitte Autran
  23. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

    • Dan H Barouch
  24. Clinic for Immunology and Rhematology, Hannover Medical School, Hanover, Germany.

    • Georg Behrens
  25. Centre d'Investigation Clinique en biothérapie, Hôpital Necker-Enfants Malades, Paris, France.

    • Marina Cavazzana
  26. AIDS Institute, The University of Hong Kong, Pok Fu Lam, Hong Kong.

    • Zhiwei Chen
  27. Institut de Recherches Cliniques de Montréal, Université de Montréal, Montréal, Quebec, Canada.

    • Éric A Cohen
  28. European AIDS Treatment Group, Italy.

    • Giulio Maria Corbelli
  29. Programme PAC-CI, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d'Ivoire.

    • Serge Eholié
  30. Harvard T. H. Chan School of Public Health, Department of Global Health and Population, Boston, Massachusetts, USA.

    • Nir Eyal
  31. Department of Medicine, Imperial College London, London, United Kingdom.

    • Sarah Fidler
  32. The B-Change Group, Manila, Philippines.

    • Laurindo Garcia
  33. National Institute of Mental Health, NIH, Bethesda, Maryland, USA.

    • Cynthia Grossman
  34. Treatment Action Group, New York, New York, USA.

    • Richard Jefferys
  35. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

    • Hans-Peter Kiem
  36. Centre for Medical Ethics and Law, Department of Medicine, Stellenbosch University, Western Cape, South Africa.

    • Keymanthri Moodley
  37. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario, Canada.

    • Peter A Newman
  38. Department of Medical Microbiology, Virology, University Medical Center Utrecht, Utrecht, Netherlands.

    • Monique Nijhuis
  39. Joint Clinical Research Centre, Kampala, Uganda.

    • Moses Supercharger Nsubuga
  40. Gladstone Institutes, University of California, San Francisco, San Francisco, California, USA.

    • Melanie Ott
  41. Westmead Millennium Institute for Medical Research, University of Sydney, Sydney, Australia.

    • Sarah Palmer
  42. Virginia San Diego Healthcare System and University of California, San Diego, San Diego, California, USA.

    • Douglas Richman
  43. Institut Pasteur, Paris, France.

    • Asier Saez-Cirion
  44. Independent HIV Education and Advocacy Consultant, San Francisco, California, USA.

    • Matthew Sharp
  45. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

    • Janet Siliciano
  46. Yerkes National Primate Research Centre, Emory University, Atlanta, Georgia, USA.

    • Guido Silvestri
  47. Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

    • Jerome Singh
  48. INSERM UMR_S912, Marseille, France.

    • Bruno Spire
  49. CARE Collaboratory Community Advisory Board, Palm Springs, California, USA.

    • Jeffrey Taylor
  50. Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.

    • Martin Tolstrup
  51. Department of Immunology and Microbial Sciences, The Scripps Research Institute, Jupiter, Florida, USA.

    • Susana Valente
  52. ViiV Healthcare, London, United Kingdom.

    • Jan van Lunzen
  53. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

    • Rochelle Walensky
  54. Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA.

    • Ira Wilson
  55. David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

    • Jerome Zack

Consortia

  1. International AIDS Society Towards a Cure Working Group

Authors

  1. Search for Steven G Deeks in:

  2. Search for Sharon R Lewin in:

  3. Search for Anna Laura Ross in:

  4. Search for Jintanat Ananworanich in:

  5. Search for Monsef Benkirane in:

  6. Search for Paula Cannon in:

  7. Search for Nicolas Chomont in:

  8. Search for Daniel Douek in:

  9. Search for Jeffrey D Lifson in:

  10. Search for Ying-Ru Lo in:

  11. Search for Daniel Kuritzkes in:

  12. Search for David Margolis in:

  13. Search for John Mellors in:

  14. Search for Deborah Persaud in:

  15. Search for Joseph D Tucker in:

  16. Search for Françoise Barre-Sinoussi in:

  17. Search for Galit Alter in:

  18. Search for Judith Auerbach in:

  19. Search for Brigitte Autran in:

  20. Search for Dan H Barouch in:

  21. Search for Georg Behrens in:

  22. Search for Marina Cavazzana in:

  23. Search for Zhiwei Chen in:

  24. Search for Éric A Cohen in:

  25. Search for Giulio Maria Corbelli in:

  26. Search for Serge Eholié in:

  27. Search for Nir Eyal in:

  28. Search for Sarah Fidler in:

  29. Search for Laurindo Garcia in:

  30. Search for Cynthia Grossman in:

  31. Search for Gail Henderson in:

  32. Search for Timothy J Henrich in:

  33. Search for Richard Jefferys in:

  34. Search for Hans-Peter Kiem in:

  35. Search for Joseph McCune in:

  36. Search for Keymanthri Moodley in:

  37. Search for Peter A Newman in:

  38. Search for Monique Nijhuis in:

  39. Search for Moses Supercharger Nsubuga in:

  40. Search for Melanie Ott in:

  41. Search for Sarah Palmer in:

  42. Search for Douglas Richman in:

  43. Search for Asier Saez-Cirion in:

  44. Search for Matthew Sharp in:

  45. Search for Janet Siliciano in:

  46. Search for Guido Silvestri in:

  47. Search for Jerome Singh in:

  48. Search for Bruno Spire in:

  49. Search for Jeffrey Taylor in:

  50. Search for Martin Tolstrup in:

  51. Search for Susana Valente in:

  52. Search for Jan van Lunzen in:

  53. Search for Rochelle Walensky in:

  54. Search for Ira Wilson in:

  55. Search for Jerome Zack in:

Competing interests

S.G.D. has received research funding and support from Gilead Sciences, Merck and ViiV, and consulting fees from Bristol-Myers Squibb, Bionor and InVirVax. J.V.L. is a full-time employee of ViiV Healthcare, a company developing and distributing antiretroviral drugs. J.W.M. is a consultant to Gilead Sciences, has received research funding from Gilead Sciences and Bristol-Myers Squibb and owns shares in Co-Crystal Pharma, Inc. D.M.M. has received research funding from Gilead Sciences, Bristol-Myers Squibb and Qura Therapeutics, consulting fees from Merck Research Laboratories, and owns common stock in Gilead Sciences A.S.-C. reports a grant from MSD, consultancy honoraria from ViiV healthcare, lecture honoraria from MSD, Gilead and Bristol-Myers Squibb. S.R.L.'s institution receives funding for investigator-initiated studies from Merck, Gilead Sciences, Viiv and Tetralogic pharmaceuticals. She has received consulting fees from and is on the advisory board of Bionor and honoraria for educational activities from Viiv and Merck.

Corresponding author

Correspondence to Steven G Deeks.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.4108

Further reading